Was ist mit Immune Response los WKN 765803 - 500 Beiträge pro Seite

[Marmay200]

Hallo, weiß jemand was mit imnr grad abgeht. gibt es gute neue nachrichten???
Über eine gehaltvolle antwort mit tiefgang würd ich mich freuen.

[Nussel]

momentan geht es ja wieder etwas aufwärts.....liegt wohl
an einer Analysteneinschätzung auf Market outperform

[chartwaechter]

Change: 0.21 (13.64%)
Gibt es etwas Neues?
Gruß
Chartwaechter

[Nussel]

Heute vorbörslich + 35%

[Nussel]

interessiert hier wohl keinen mehr

[chartwaechter]

Heute wird der Kurs wieder zerisssen, wie es aussieht.

[Marmay200]

Weiß jemand was jetzt nu wieder hier los ist. Folgende Meldung hab ich bei imnr.com gefunden:

September 28, 2004

The Immune Response Corporation Announces REMUNE® Restores HIV-1-Specific Activity of CD4+ and CD8+ T Cells, Similar to Anti-HIV Immune Responses Seen in Long-Term Nonprogressors
Results Published In September Issue of Journal of Experimental Medicine

Carlsbad, California – September 28, 2004 – An investigational treatment called REMUNE® (HIV-1 Immunogen) appears to boost both HIV-1-specific CD4+ and HIV-1-specific CD8+ T cell lymphocyte activity in chronically HIV-1 infected patients. The results are published in the September 20th issue of the Journal of Experimental Medicine (vol 200, pgs. 701-712).

REMUNE® is being developed by The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis.

“These results provide additional evidence that REMUNE® can induce the types of immune responses that could potentially show a benefit in delaying disease progression in HIV-infected subjects,” said John N. Bonfiglio, Ph.D., Chief Executive Officer of The Immune Response Corporation. “Ability to generate both CD4+ and CD8+ HIV-1 specific immune responses is observed in long-term nonprogressors, who are a small percentage of HIV-positive patients that are able to live with the HIV virus for extended periods of time without progressing to AIDS.”

“The ability to emulate this immunologic profile with an HIV therapeutic vaccine is one of the goals of the ongoing research in this area. It may be an important indicator of clinical utility that REMUNE® can induce these responses. We are continuing to study this important aspect of REMUNE®,” continued Dr. Bonfiglio.

T-lymphocytes include subsets of CD4+ cells and CD8+ cells and play an important role in the progression of HIV-1 and other viral infections. However, the interaction between these subsets of cells is poorly understood. The current study sheds light on this interaction and indicates that restoring CD4+ T cell responses with REMUNE® enhances HIV-1–specific CD8+ T cell proliferation.

The researchers led by Marcus Altfeld, M.D., with the Massachusetts General Hospital and Division of AIDS, Harvard Medical School, recruited 35 HIV-1 infected individuals. Of those, 18 had recent primary HIV-1 infection; an additional 7 had a long-term non-progressive disease course, and 10 individuals had chronic progressive HIV-1 infection. HIV-1 specific responses were evaluated in these individuals, and compared with responses observed in T cells that had previously been obtained from subjects participating in a clinical study of REMUNE®.

By measuring responses in individuals at different stages of the disease, the researchers demonstrated that HIV-1-specific CD8+ T cells proliferated rapidly in acute infection, but lost this ability as viral replication progressed and was not observed in individuals with chronic infection. This response was maintained, however, in individuals with long-term nonprogressive disease, and appeared to be dependent on interluken-2 (IL-2) secretion by CD4+ T helper cells.

Samples derived from patients in a previous REMUNE® study were similarly analyzed. Five patients had received REMUNE® and five had received IFA placebo. The results showed that both HIV-1–specific CD4+ T cells and CD8+ T cells proliferated in the REMUNE® group but not in the controls. They also demonstrated significantly higher HIV-specific IL-2 production by CD4+ T cells in REMUNE® treated individuals than in the controls (p=0.05). These results suggest that in vivo augmentation of CD4+ T cell response with REMUNE® can restore HIV-1 specific CD8+ T cell lymphoproliferative immune responses in vivo via a mechanism involving CD4+ production of IL-2.

REMUNE® is in Phase II development by The Immune Response Corporation and is not approved by any regulatory agencies in any country at this time. The authors of this paper have not received research funding support from the company for this study. Inquiries related to the paper should be directed to Marcus Altfeld, M.D., at Massachusetts General Hospital in Boston.

About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVaxTM, which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

Wer mir eine kurze sinnvolle inhaltsangabe geben kann der möge sie hier doch bitte schreiben.

Danke im voraus

Marcus

[Marmay200]

Ist hier noch irgendjemand der sich für diese Aktie interessiert?
Wenn ja, würde mich mal interessieren was derjenige oder diejenigen von den momentanen Nachrichten hält oder was schönes gehört hat.

Schönes Wochenende

Marcus

[ceres]

Moin, die Experten von "Hot Stock Investor" halten IMNR für ein interessantes Investment. Wer mehr wissen möchte, sollte sich bei aktiencheck.de "Analysen" nähere Infos holen. Hört sich nicht schlecht an. Die Aktie ist hochspekulativ und nichts für schwache Nerven.

[mehmeto]

Die immunes Wartekorporation verkündet die Expansion seines mehrfache Sklerose-klinischen Programms
Die immunes Wartekorporation verkündet die Expansion seines mehrfache Sklerose-klinischen Programms



BW5439 DEZ 08.2004 7:04 PAZIFISCHES 10:04 ÖSTLICH



(BW) (CA-IMMUNE-RESPONSE) (IMNR) die immune Antwort CorporationAnnounces die Expansion seines mehrfache Sklerose-klinischen Programms

Geschäft Herausgeber/Gesundheit/medizinische Verfasser
BIOWIRE2K

CARLSBAD, Calif. --(GESCHÄFT LEITUNG)--8. Dez. 2004--


Anregenclinical Data und Large Unmet Market Need Drive Company Strategie

Die immunes Wartekorporation (Nasdaq: IMNR), ein biopharmaceuticalcompany engagiertes zum Werden ein Führen immun-gründete Therapie companyin HIV und mehrfache Sklerose (MS), verkündet die Expansion seines MSclinical Entwicklungsprogramms.
"Gründete auf den einleitenden NeuroVax (TM) Daten und zeigte eine immune 94percent Ansprechgeschwindigkeit, dargestellt an den AAN Sitzung earlierthis Jahr, haben wir die Geschäft Entscheidung zum refocus Betriebsmittel toexpand getroffen und unser MSEntwicklungsprogramm beschleunigen, einschließlich den anstellenofadditional Personal, zum es zu stützen,", sagte John N. Bonfiglio, Ph.D., Präsident und Generaldirektor des immunen ResponseCorporation. "Letztes week´s Brett der Directors´ Sitzung bestätigte thisstrategy und es ist unsere Absicht, zum unseres Produktmappe toinclude auszugleichen ein konkurrenzfähigeres MSEntwicklungsprogramm, beim Fortschritt torapidly fortsetzen unser HIV Programm."
"Außenseite Forschung scheint, zu zeigen, daß immune Antworten zum aclinical Nutzen für den Patienten gleichstellen. Dieses regt uns advanceNeuroVax (TM) zur Entwicklung schnellstmöglich," sagte GeorgiaTheofan, Ph.D., Vizepräsident der klinischen Entwicklung an ImmuneResponse Corporation an. "Trotz der neuen Behandlungwahlen, MS bleibt die adebilitating und verheerende Krankheit, die fast Hälfte ein millionpeople in den US alleine beeinflußt. NeuroVax (TM) ist immun-gegründet, eine immunes System Krankheit therapytargeting, und wir, schauen vorwärts, toreviewing die neuen Daten, folgendes Jahr."
Die Strategie für die Entwicklung des MSbereichs schließt theexpansion und Beendigung des gegenwärtigen fortwährenden Phase II Versuches, theinitiation eines größeren neuen Versuches ein, der entworfen ist, um das clinicalbenefit von NeuroVax (TM) und die Suche nach einem korporativen Partner tohelp das Firmanehmen dieses Programm zur Kommerzialisierung zu überprüfen.
Zusätzlich hat die Firma eine Anwendung für aNational Institute Gesundheit (NIH) der Bewilligung eingereicht, um additionalNeuroVax (TM) Studien und Analysen zu stützen. Zusätzliche Bewilligungen und das Outsidefunding werden gesucht, um das Company´s Betriebsmittel tocontinue ein konkurrenzfähiges timeline ohne vergleichendes scientificintegrity oder andere klinische Programme zu ergänzen.
Die Firma stellt eine neue wissenschaftliche Beratungsstelle (SAB) der MSexperten her, um zu helfen, die klinische Forschung, protocoldevelopment zu führen und maximiert das Potential von NeuroVax (TM). Das SAB willconvene frühem 2005 zum ersten Mal und das Treffen regelmäßig zum reviewdata und beraten die Firma.

Über MS und NeuroVax (TM)

Mehrfache Sklerose (MS) ist ein Autoimmunkrankheit, in dem theimmune System, die body´s Hauptverteidigung gegen fremdes substancessuch als Bakterium, irrtümlich normale Gewebe des centralnervous Systems in Angriff nimmt. Sie betrübt ungefähr 400.000 Leute in den weltweiten Vereinigten Staaten und mehr als 2.5 in Million. Spezifisch benannten verursachten die diseaseresults in der Beschädigung eines fetthaltigen Gewebes das myelin, das andprotects Nerv Fasern umgibt und (Sklerose) dieses interfereswith schrammend das normale Getriebe der Nerv Antriebe. Diese Beschädigung führt der Reihe nach zu eine Vielzahl von chronischem und in hohem Grade einzelne und unpredictableneurological Symptome und reicht von der Bewegung und Balance Probleme tovision Beeinträchtigung. Die Krankheit wird groß durch Aktivierung der aspecific Teilmenge der patient´s besitzen weiße Blutzellen, T-Zellen verursacht, thatthen Angriff das myelin und sind groß verantwortlich für diseaseprogression. Die Firma fordert, daß TCR Peptide mit IncompleteFreund´s Hilfe (IFA) die regelnden T-Zellen anregen, die diese autoreactive pathogenen T-Zellen ofsuppressing fähig sind. NeuroVax (TM), whichcombines drei TCR Peptide mit

WARNING: SYSTRAN did not translate the document entirely. The document exceeds the maximum size allowed by the solution.(4096 bytes for plain text)

IFA, was designed to increase thelikelihood of this immune reaction.
NeuroVax(TM) is in Phase II development by The Immune ResponseCorporation and is not approved by any regulatory agencies in anycountry at this time.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq:IMNR) is abiopharmaceutical company dedicated to becoming a leading immune-basedtherapy company in HIV and multiple sclerosis (MS). The Company´s HIVproducts are based on its patented whole-killed virus technology,co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immuneresponses. REMUNE(R), currently in Phase II clinical trials, is beingdeveloped as a first-line treatment for people with early-stage HIV.We have initiated development of a new immune-based therapy, IR103,which incorporates a second-generation immunostimulatoryoligonucleotide adjuvant and is currently in Phase I/II clinicaltrials in Canada and the United Kingdom.
The Immune Response Corporation is also developing an immune-basedtherapy for MS, NeuroVax(TM), which is currently in Phase II and hasshown potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation at www.imnr.com.

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas should, could, will, might, plan, projection, forecast, expect,guidance, potential and developing. Actual results could varymaterially from those expected due to a variety of risk factors,including whether the Company will continue as a going concern andsuccessfully raise proceeds from financing activities sufficient tofund operations and additional clinical trials of REMUNE(R),NeuroVax(TM)or IR103, the uncertainty of successful completion of anysuch clinical trials, the fact that the Company has not succeeded incommercializing any drug, the risk that REMUNE(R), NeuroVax(TM)orIR103 might not prove to be effective as either a therapeutic orpreventive vaccine, whether future trials will be conducted andwhether the results of such trials will coincide with the results ofREMUNE(R), NeuroVax(TM)or IR103 in preclinical trials and/or earlierclinical trials. These risks, among others, are set forth in TheImmune Response Corporation´s SEC filings including, but not limitedto, its Annual Report on Form 10-K for the year ended December 31,2003, and its subsequent Quarterly Reports on Form 10-Q. The Companyundertakes no obligation to update the results of theseforward-looking statements to reflect events or circumstances aftertoday or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune ResponseCorporation. NeuroVax(TM) is a trademark of The Immune ResponseCorporation.

--30--EH/la* CONTACT: The Immune Response Corporation Michael K. Green, 760-431-7080 (Investors) [e-mail] or Sam Brown Inc. Corporate Communication Laura Silver, 310-551-9940 (Media) [e-mail] KEYWORD: CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL PRODUCT SOURCE: The Immune Response CorporationCopyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 16:04 08.12.04